Bisoprolol

Drug Profile

Bisoprolol

Alternative Names: Bisoprolol fumarate; Concor; Maintate; TA-4708

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck KGaA
  • Developer Merck KGaA; Mitsubishi Tanabe Pharma Corporation
  • Class Antihypertensives; Heart failure therapies; Ischaemic heart disorder therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris; Arrhythmias; Atrial fibrillation; Chronic heart failure; Hypertension

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 17 Jun 2013 Launched for Arrhythmias in Japan (PO)
  • 17 Jun 2013 Launched for Atrial fibrillation (tachycardiac) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top